key: cord-0822622-i6u1x0xq
authors: Yinda, Claude Kwe; Port, Julia R.; Bushmaker, Trenton; Fischer, Robert J.; Schulz, Jonathan E.; Holbrook, Myndi G.; Shaia, Carl; de Wit, Emmie; van Doremalen, Neeltje; Munster, Vincent J.
title: Prior aerosol infection with lineage A SARS-CoV-2 variant protects hamsters from disease, but not reinfection with B.1.351 SARS-CoV-2 variant
date: 2021-05-05
journal: bioRxiv
DOI: 10.1101/2021.05.05.442780
sha: e88ba8e849eadb1966b056368d0ecd2337467756
doc_id: 822622
cord_uid: i6u1x0xq

The circulation of SARS-CoV-2 has resulted in the emergence of variants of concern (VOCs). It is currently unclear whether previous infection with SARS-CoV-2 provides protection against reinfection with VOCs. Here, we show that low dose aerosol exposure to hCoV-19/human/USA/WA-CDC-WA1/2020 (WA1, lineage A), resulted in a productive mild infection. In contrast, low dose of SARS-CoV-2 via fomites did not result in productive infection in the majority of exposed hamsters and these animals remained non-seroconverted. After recovery, hamsters were re-exposed to hCoV-19/South African/KRISP-K005325/2020 (VOC B.1.351) via an intranasal challenge. Seroconverted rechallenged animals did not lose weight and shed virus for 3 days. They had little infectious virus and no pathology in the lungs. In contrast, shedding, weight loss and extensive pulmonary pathology caused by B.1.351 replication was observed in the non-seroconverted animals. The rechallenged seroconverted animals did not transmit virus to naïve sentinels via direct contact transmission, in contrast to the non-seroconverted animals. Reinfection with B.1.351 triggered an anamnestic response that boosted not only neutralizing titers against lineage A, but also titers against B.1.351. Our results confirm that aerosol exposure is a more efficient infection route than fomite exposure. Furthermore, initial infection with SARS-CoV-2 lineage A does not prevent heterologous reinfection with B.1.351 but prevents disease and onward transmission. These data suggest that previous SARS-CoV-2 exposure induces partial protective immunity. The reinfection generated a broadly neutralizing humoral response capable of effectively neutralizing B.1.351 while maintaining its ability to neutralize the virus to which the initial response was directed against.

Introduction experimental SARS-CoV-2 animal models, the exposure route and dose are linked to disease 51 severity [1, 2] . The evolution of SARS-CoV-2 has led to the emergence of several new variants. 52

Within these novel emerging SARS-CoV-2 variants, there are variants of interest (VOIs) and 53 variants of concern (VOCs). VOCs are defined by phenotypic changes including enhanced 54 transmission, increased pathogenicity and decreased efficacy of prophylactic and therapeutic 55 countermeasures [3, 4] . Some VOCs display specific mutations in the spike protein that reduce 56 binding affinity of neutralizing antibodies [5] [6] [7] [8] 

Heat-inactivated γ -irradiated sera were two-fold serially diluted in DMEM2. 100 TCID 50 of 155 SARS-CoV-2 strain nCoV-WA1-2020 or hCoV-19/South African/KRISP-K005325/2020 was 156 added. After 1 h of incubation at 37°C and 5% CO 2 , the virus:serum mixture was added to 157 VeroE6 cells. CPE was scored after 5 days at 37°C and 5% CO 2 . The virus neutralization titer 158 was expressed as the reciprocal value of the highest dilution of the serum which still inhibited 159 virus replication. 160

Results 162

hamsters 164 We previously demonstrated that hamsters become uniformly infected after an experimental 165 aerosol or fomite exposure with a relatively high dose of 8x10 4 TCID 50 SARS-CoV-2 [2]. To 166 increase our understanding of the relationship between exposure route and infectious dose we 167 exposed Syrian hamsters to SARS-CoV-2 administered via low dose aerosols or fomites. For the 168 aerosol inoculation route, two groups (N = 4) of hamsters were exposed to 1.1x10 2 or 2.5x10 1 169 TCID 50 of SARS-CoV-2 strain nCoV-WA1-2020 (WA1, lineage A; indicated as Aerosol 10 2 and 170 and 10 1 TCID 50 of SARS-CoV-2 WA1 (indicated as Fomite 10 3 , 10 2 and 10 1 ). No significant and 10 3 groups, and only one animal in the Fomite 10 2 group demonstrated prolonged shedding 177 until 9 DPI (Fig 1 b) . To compare the magnitude of shedding between the two aerosol groups, 178

we performed an area under the curve (AUC) analysis. No significant difference between the two 179 groups was observed (median Aerosol 10 2 = 46.16 and Aerosol 10 1 = 60.57 AUC log 10 180 copies/exp, N = 4, Mann-Whitney test, p = 0.0571) (Fig 1 c) . All aerosol-exposed hamsters 181 seroconverted by 14 DPI, as measured by anti-spike ELISA. In contrast, seroconversion was 182 only detected in the single animal which demonstrated prolonged shedding in the Fomite 10 2 183 group. The magnitude of the humoral response was higher in Aerosol 10 2 animals than in the 184 Aerosol 10 1 animals (Fig 1 d, median Aerosol 10 2 = 409,600 and Aerosol 10 1 = 51,200 ELISA 185 titer, N = 4, Mann Whitney test, p = 0.0286). This study confirms that aerosol exposure is a 186 highly efficient infection route in hamsters, whereas fomite exposure is less so. 187

Up to 10 7 TCID 50 SARS-CoV-2/g tissue was detected in the lungs of non-seroconverted animals 203 while only one of the seroconverted animals was positive for infectious virus with a titer of 10 2.5 204 TCID 50 /g (Fig 2 e) . Spike protein amino acid substitutions Q677H and R682W were completely 205 cleared from the virus population and no longer detected in lung tissue of virus positive animals. 206

Upon histopathological analysis lung tissue from seroconverted animals was normal (3 a, b , e, f) 207 while the lungs of the 2 non-seroconverted animals demonstrated alveolar inflammation 208 consisting of macrophages and neutrophils, as well as variable amounts of hemorrhage, fibrin 209 and edema (Fig 3 c, d, g, h) consistent with a lower respiratory tract infection with SARS-CoV-210 2. Immunohistochemistry using a monoclonal antibody against SARS-CoV-2 demonstrated viral 211 antigen in bronchial and bronchiolar epithelium, type I and II pneumocytes as well as pulmonary 212 macrophages within the non-seroconverted animals (Fig 3 k, l) , but not in the seroconverted 213 animals (Fig 3 i, j) . 214

Rechallenge with VOC B.1.351 led to an increase in the humoral response. ELISAs conducted at 215 5 DPR showed seroconverted rechallenged animals had increased levels of antibody titers 216 against lineage A SARS-CoV-2 spike protein (median = 1,638,400 ELISA titer, N = 3) 217 compared to the minimal levels of antibodies in the two non-seroconverted animals (median = 218 800, N = 2) (Fig 2 f) for the presence of sgRNA. In the two sentinels co-housed with a non-seroconverted 239 rechallenged hamster, we observed shedding of sgRNA from the sentinel hamsters (Fig 4 a) . In 240 contrast, in swabs obtained from sentinels co-housed with seroconverted rechallenged hamsters, 241 no SARS-CoV-2 RNA was detected at any timepoint suggesting that no transmission occurred. 242

The efficiency of transmission was also evaluated by serology at 14 DPE. Only the two sentinels 243 co-housed with a non-seroconverted rechallenged hamster had seroconverted, as measured by 244 anti-spike ELISA ( Table 1) . We thus conclude that none of the seroconverted animals 245 transmitted B.1.351 to sentinels, whereas both non-seroconverted animals transmitted virus to 246 sentinels. 247

To understand why transmission did not occur for sentinels co-housed with seroconverted 248 hamsters, we determined the level of infectious virus in oropharyngeal swabs obtained from 249 donor animals. Infectious virus could be detected in swabs from both non-seroconverted animals 250 at 2 DPR (median = 1170 TCID 50 /ml, N = 2), while infectious virus was detected in only one of 251 the seroconverted animals and at a very low level (10 TCID 50 /ml) (Fig 4 b) (88% and 81%, respectively). These major variant amino acid SNPs were absent on 5 DPR, 285 suggesting that they are rapidly selected against in the SARS-CoV-2 hamster model. 286

Nonetheless, the substitutions which are thought to be important in immune evasion, such as 287 E484K, are still present in the virus stock. Furthermore, efficient upper and lower respiratory 288 tract replication and lung pathology was observed in infected hamsters. We thus do not believe 289 that the presence of these additional amino acid substitutions, present as a quasispecies, affect the 290 data interpretation. 291

Our results provide more experimental support to the consensus that aerosol exposure is a more 292 efficient infection route than fomite exposure [37] . Whereas initial infection with SARS-CoV-2 shedding, and did prevent disease and lower respiratory tract replication and onward plasma and vaccine-induced neutralizing antibodies [38] [39] [40] [41] 

Defining the Syrian hamster as a highly susceptible 5

Resistance of SARS-CoV-2 variants to neutralization by 334 monoclonal and serum-derived polyclonal antibodies

Reduced neutralization of SARS-CoV-2 B.1.1.7 variant 336 by convalescent and vaccine sera

Antibodies elicited by SARS-CoV-2 infection and 338 boosted by vaccination neutralize an emerging variant and SARS-CoV-1

SARS-CoV-2 variant B.1.1.7 is susceptible to neutralizing 341 antibodies elicited by ancestral spike vaccines

SARS-CoV-2 variants B.1.351 and B.1.1.248: Escape from 343 therapeutic antibodies and antibodies induced by infection and vaccination

SARS-CoV-2 B.1.1.7 sensitivity to mRNA 346 vaccine-elicited, convalescent and monoclonal antibodies

Emergence and rapid spread of a new severe acute 348 respiratory syndrome-related coronavirus 2 (SARS-CoV-2) lineage with multiple spike mutations 349 in South Africa

Detection of 2019 novel coronavirus (2019-nCoV) by 351 real-time RT-PCR

Efficacy of antibody-based therapies against 353

Middle East respiratory syndrome coronavirus (MERS-CoV) in common marmosets

Pathogenesis and transmission of SARS-CoV-2 in golden 356 hamsters

Transmission of Influenza Virus via Aerosols and Fomites 358 in the Guinea Pig Model

Exaggerated risk of transmission of COVID-19 by fomites

Sensitivity of infectious SARS-CoV-2 B.1.1.7 and B.1.351 382 variants to neutralizing antibodies

Antibody Resistance of SARS-CoV-2 Variants B.1.351 and 384 B.1.1.7

mRNA-1273 vaccine induces neutralizing antibodies against 386 spike mutants from global SARS-CoV-2 variants

Neutralization of SARS-CoV-2 spike 69/70 deletion, E484K and 388 N501Y variants by BNT162b2 vaccine-elicited sera

SARS-CoV-2 501Y.V2 escapes neutralization by South 390

African COVID-19 donor plasma

Genomic evidence for reinfection with SARS-CoV-2: 392 a case study. The Lancet Infectious Diseases

Reinfection risk of novel coronavirus (COVID-19): 394 A systematic review of current evidence

Evidence of Severe Acute Respiratory Syndrome Coronavirus

Reinfection After Recovery from Mild Coronavirus Disease

Syrian hamsters as a small animal model for 399

SARS-CoV-2 infection and countermeasure development

SARS-CoV-2 infection induces protective immunity and limits